2 min readResearchers Harness the Immune System to Fight Pancreatic Cancer
Philadelphia, PA – Pancreatic cancer ranks as the fourth-leading cause of cancer death in the United States, and is one of the most deadly forms of cancer, due to its resistance to standard treatments with chemotherapy and radiation therapy and frequently, its late stage at the time of diagnosis.
A group of researchers led by the University of Pennsylvania’s Perelman School of Medicine and Abramson Cancer Center, in collaboration with scientists from the University of Pittsburgh and University of Washington, published results of a clinical trial in which the standard chemotherapy drug for this disease, gemcitabine, was paired with an agonist CD40 antibody, resulting in substantial tumour regressions among some patients with advanced pancreatic cancer. By using a novel, real-time imaging approach to monitor tumour response to the immunotherapy, the team also found differences how primary and metastatic disease sites shrank. Their work appears online this month in Clinical Cancer Research.
“We’re now using imaging to understand the treatment heterogeneity that one can see in immunotherapy – not all tumours within a patient’s body react the same way, even in the face of powerful treatments, and now we have a way to follow these unique treatment responses in patients in real-time,” said lead author Dr. Gregory Beatty, an assistant professor in the division of Hematology/Oncology in the Abramson Cancer Center.
The report builds on preliminary results of findings in both humans and mice published in Science in 2011. The new approach exploits an immune reaction in the microenvironment of the patient’s primary tumour by targeting an immune cell surface molecule CD40 to turn a type of white blood cell known as macrophages against the tumour by causing them to attack the stroma, the fibrotic supporting tissue of the tumour that acts as a defensive barrier to standard therapies. The treatment ate away at this stroma, ultimately causing substantial shrinkage of some primary tumours, and affecting the metabolic activity of both primary and metastatic lesions. Of 21 patients treated with the drug combination, five patients who received at least one treatment course developed a partial response, defined as a decrease in tumour size of at least 30 percent.
The new study also measured the effectiveness of applying a new approach to FDG/PET-CT imaging, to reveal the metabolic responses of individual tumours. FDG/PET-CT uses a radioactive glucose tracer to pinpoint glucose uptake within tumours, revealing the places where cells are metabolically active. Typically physicians and radiologists report only the maximum uptake of glucose within a tumour using this imaging technique; however, the new study showed that glucose metabolism can be quantified within individual tumours or within organs, and throughout the entire body, to provide a measure of total tumour burden.
The team found that while primary tumours seemed to respond more or less uniformly with each treatment cycle, tumours varied in their reactions to treatment. “We incorporated imaging as early as two weeks after the first dose of treatment, and we’re able to see changes and responses in terms of glucose metabolism even at this early time point in treatment, which predicted how well patients would respond two months later,” Beatty says. The team hopes to apply the use of FDG/PET-CT to monitoring treatment responses during other immune-based therapies in pancreas cancer.
Determining the reasons for these varying responses will be an important next step in this work. The unique imaging approach, Beatty notes, is revealing new insight into the biology of pancreas cancer and its treatment resistance. This allows the research team to expedite progress through a unique model that moves quickly back and forth between the lab and the clinic: “We’re taking it back to the bench and at the same time, applying it at the bedside with additional clinical trials.”
The most commonly observed side effect of the treatment was cytokine release syndrome, typically manifested as chills and rigours. One patient with a previous history of vascular disease experienced a stroke shortly after starting therapy.
Publication: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Gregory L Beatty et al. Clin Cancer Res clincanres (August 27, 2013): http://clincancerres.aacrjournals.org/content/early/2013/08/31/1078-0432.CCR-13-1320.long